About: A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 17 October 2011

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в жовтні 2011 (uk) im Oktober 2011 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 17 October 2011 (en) artículu científicu espublizáu n'ochobre de 2011 (ast)
publication date	wds:Q82066071-2BF9445B-7D83-491C-B8C4-45AE28EA504A
publication date	2011-10-17 00:00:00Z (xsd:dateTime)
author name string	wds:Q82066071-1464DA1F-2730-4AF3-99A9-598FEE7C0FA6 wds:Q82066071-30BCA6C1-FF40-4FF8-A48B-F713AAA34615 wds:Q82066071-3C8C8A08-4AD5-4339-BEDC-C7900FB4F904 wds:Q82066071-4A84632E-103D-4C88-A8BB-D16B0C88CFB9 wds:Q82066071-58CB9304-1D10-496F-8324-C33BEC2345CB wds:Q82066071-59CDD9A4-DC28-49C6-A25C-6B1E9170D32D wds:Q82066071-8E0E30FE-6F81-403D-BE48-E482C1503955 wds:Q82066071-C151AD31-7D17-47AC-89A3-EC23C4A1A9A8 wds:Q82066071-D0687041-F729-41C0-A4B7-CBE5B964B0DC wds:Q82066071-F9D39AD5-22AA-4221-BA6E-256DBCE5E798
author name string	Joel M Kremer Sriram Krishnaswami Juan Gomez-Reino Samuel H Zwillich Gene Wallenstein David Gruben Virginia Pascual-Ramos Keith S Kanik Bethanie E Wilkinson Carol A Connell
rdfs:label	A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone (en) A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone (nl)
skos:prefLabel	A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone (en) A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone (nl)
name	A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone (en) A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone (nl)
author	wds:Q82066071-721A3D40-4546-4CBC-84F7-F8E2DFFE8797 wds:Q82066071-F768A3B1-037C-4B9B-8EFB-58AF4992C627
author	Stanley B Cohen Jonathan French
title	wds:Q82066071-C078D43F-82F6-4DCC-BAD0-00C02E49CBE1
title	A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone (en)
page(s)	wds:Q82066071-4147DD29-0179-494F-88B5-6697592A6109
page(s)	970-981
instance of	wds:Q82066071-475C0A46-B84B-42FE-B26D-252159ACD15C
instance of	scholarly article
main subject	wds:Q82066071-37615D35-F3E2-47F9-9205-18EFD6FD7EC5 wds:Q82066071-5335D562-6CC0-4EE4-896B-A609DB02E26A wds:Q82066071-BFDC32CA-0502-474D-B246-F08E6186A2C2 wds:Q82066071-F319A1BB-BDBD-4969-A08A-A6ECACADB4E3
main subject	wd:Q3530324 rheumatoid arthritis placebo wd:Q422232
PubMed ID	wds:Q82066071-8C505348-BF2C-41EE-9439-A3D1055FDE33
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/22006202
PubMed ID	22006202
published in	wds:Q82066071-BBFA638E-F321-4502-97F6-6BBE0E0B899B
published in	Arthritis and Rheumatism
issue	wds:Q82066071-1A415270-76C8-40F9-9C5A-ED5BEF23768D
volume	wds:Q82066071-A7D835DB-2408-47DD-8D0A-1012A1FD69B1
issue	4
volume	64
DOI	wds:Q82066071-3276868A-8E8D-43FD-8FEE-96226311EE9E
DOI	http://dx.doi.org/10.1002/ART.33419
DOI	10.1002/ART.33419
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q82066071
is cites work of	Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease Covalent docking of large libraries for the discovery of chemical probes Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits JAK and STAT signaling molecules in immunoregulation and immune-mediated disease Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studies Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis Interleukin-27: balancing protective and pathological immunity Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol. Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2. Kinase inhibitors: a new class of antirheumatic drugs Tofacitinib: a review of its use in adult patients with rheumatoid arthritis Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis Back to the future: oral targeted therapy for RA and other autoimmune diseases The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential The JAK-STAT pathway: impact on human disease and therapeutic intervention Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group IL-7- and IL-15-mediated TCR sensitization enables T cell responses to self-antigens Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme A clinical therapeutic protein drug-drug interaction study: coadministration of denosumab and midazolam in postmenopausal women with osteoporosis Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib Tofacitinib for acute rheumatoid arthritis patients who have had an inadequate response to disease-modifying antirheumatic drug (DMARD): a systematic review and meta-analysis Tofacitinib

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software